Our earlier studies with tissue-specific oncolytic viruses in prostate cancer patients revealed an initial viral replication (CV706) peak in the patient plasma after 3 days of viral inoculation which was depleted within ten days in the absence of preexisting circulating anti-Ad5 antibodies, suggesting a compromised viral replication [23]. Here, PSEN2 is linked to prostate cancer.